[BostonCard]

https://www.cnn.com/2020/08/10/health/co...index.html



I wish this weren't framed vis a vis whether the results will be back before the election.  I always thought a 2020 result was ambitious, but was hoping we would have something we could give to people at high risk.  Of course, Moderna is not the only shot on goal, and maybe the AZ/Oxford or BioNTech/Pfizer collaborations will get an answer more quickly.



I will also note that enrollments always start out slow and ramp up, so what Moderna is experiencing is not unusual.



BC

What a great headline.  CNN is garbage.

Perhaps CNN was onto something.

https://www.fiercebiotech.com/biotech/tr...ine-report

(sorry I didn't link to the original FT article, but it's behind a paywall and I don't have access).

President Donald Trump is considering fast-tracking the authorization of AstraZeneca’s COVID-19 vaccine to ensure a jab is available in time for the November election, according to the Financial Times. The mooted plan is to allow AstraZeneca to gain emergency use authorization (EUA) on the basis of a 10,000-subject U.K. clinical trial.

I sincerely hope we get a safe and effective vaccine as soon as possible.  I think generally, pushing all levers to move quickly in vaccine development has been the one aspect of the response to the pandemic for which Trump deserves praise.  But the potential for all this to turn sideways in order to meet an artificial deadline is substantial.  And rushing a vaccine to market that later is found to have safety concerns could cause lasting damage to the country's perception of vaccines.  Unfortunately, those might not be seen until well after the election.

BC

[BostonCard]

https://www.cnn.com/2020/08/10/health/co...index.html



I wish this weren't framed vis a vis whether the results will be back before the election.  I always thought a 2020 result was ambitious, but was hoping we would have something we could give to people at high risk.  Of course, Moderna is not the only shot on goal, and maybe the AZ/Oxford or BioNTech/Pfizer collaborations will get an answer more quickly.



I will also note that enrollments always start out slow and ramp up, so what Moderna is experiencing is not unusual.



BC

What a great headline.  CNN is garbage.

Perhaps CNN was onto something.

https://www.fiercebiotech.com/biotech/tr...ine-report

(sorry I didn't link to the original FT article, but it's behind a paywall and I don't have access).

President Donald Trump is considering fast-tracking the authorization of AstraZeneca’s COVID-19 vaccine to ensure a jab is available in time for the November election, according to the Financial Times. The mooted plan is to allow AstraZeneca to gain emergency use authorization (EUA) on the basis of a 10,000-subject U.K. clinical trial.

I sincerely hope we get a safe and effective vaccine as soon as possible.  I think generally, pushing all levers to move quickly in vaccine development has been the one aspect of the response to the pandemic for which Trump deserves praise.  But the potential for all this to turn sideways in order to meet an artificial deadline is substantial.  And rushing a vaccine to market that later is found to have safety concerns could cause lasting damage to the country's perception of vaccines.  Unfortunately, those might not be seen until well after the election.

BC